Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949590 | 0.86 | NPSR1 (0.47) | EGFRERBB2EPHX2PPARGGRIN1 | |
| SCHEMBL11949602 | 0.83 | EGFR (0.58) | EGFRERBB2EPHX2PPARGGRIN1 | |
| SCHEMBL13946647 | 0.82 | EGFR (0.52) | EGFRERBB2EPHX2PPARGGRIN1 | |
| SCHEMBL17263515 | 0.81 | EGFR (0.45) | EGFRERBB2EPHX2PPARGGRIN1 | |
| SCHEMBL14093248 | 0.81 | GABRA1 (0.52) | EGFRERBB2GRIN1GRIN2BRECQL | |
| SCHEMBL215702 | 0.81 | EGFR (0.53) | EGFRERBB2EPHX2PPARGRECQL | |
| SCHEMBL21057948 | 0.81 | EGFR (0.53) | EGFRERBB2EPHX2PPARGGRIN1 | |
| SCHEMBL21058074 | 0.81 | EGFR (0.50) | EGFRERBB2EPHX2PPARGGRIN1 | |
| SCHEMBL30729935 | 0.81 | EGFR (0.53) | EGFRERBB2EPHX2PPARGRECQL | |
| SCHEMBL5665244 | 0.81 | EGFR (0.50) | EGFRERBB2EPHX2PPARGGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| US-7488823-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | EGFR 5/4885ERBB2 1/4885EPHX2 2602/4885 |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | EGFR 5/4885ERBB2 1/4885EPHX2 2602/4885 |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | ABL1, ERBB4, ERBB2 | EGFR 5/4885ERBB2 3/4885EPHX2 2114/4885 |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | EGFR 5/4885ERBB2 1/4885EPHX2 2602/4885 |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | PPIP5K2, PIK3CA, PHKA1 | EGFR 718/4885ERBB2 446/4885EPHX2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.